Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841333 | 0.85 | ABL1 (0.44) | TAAR1TP53MAPTTHRBSMN1; SMN2 | |
| SCHEMBL7489900 | 0.80 | BRAF (0.44) | MAPTBRAFCYP2C9 | |
| SCHEMBL6845313 | 0.78 | TAAR1 (0.49) | TAAR1TP53MAPTTHRBSMN1; SMN2 | |
| SCHEMBL6845311 | 0.78 | TAAR1 (0.49) | TAAR1TP53MAPTTHRBSMN1; SMN2 | |
| SCHEMBL6846684 | 0.76 | TP53 (0.48) | TAAR1TP53MAPTTHRBSMN1; SMN2 | |
| SCHEMBL4248664 | 0.73 | MAPT (0.64) | TAAR1TP53MAPTTHRBSMN1; SMN2 | |
| SCHEMBL3647615 | 0.72 | TAAR1 (1.00) | TAAR1MAPTSMN1; SMN2 | |
| SCHEMBL29690457 | 0.72 | TAAR1 (1.00) | TAAR1MAPTSMN1; SMN2 | |
| SCHEMBL22466142 | 0.71 | TAAR1 (0.48) | TAAR1TP53MAPTTHRBSMN1; SMN2 | |
| SCHEMBL29377364 | 0.71 | TAAR1 (0.48) | TAAR1TP53MAPTTHRBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | TAAR1 3516/4885TP53 397/4885MAPT 899/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | TAAR1 3516/4885TP53 397/4885MAPT 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.